Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 18;24(12):10308.
doi: 10.3390/ijms241210308.

Target and Cell Therapy for Atherosclerosis and CVD

Yuliya V Markina  1 , Tatiana V Kirichenko  1 , Taisiya V Tolstik  1 , Anastasia I Bogatyreva  1 , Ulyana S Zotova  1 , Vadim R Cherednichenko  1 , Anton Yu Postnov  1 , Alexander M Markin  1   2
Affiliations
Review

Target and Cell Therapy for Atherosclerosis and CVD

Yuliya V Markina et al. Int J Mol Sci. .

Abstract

Cardiovascular diseases (CVD) and, in particular, atherosclerosis, remain the main cause of death in the world today. Unfortunately, in most cases, CVD therapy begins after the onset of clinical symptoms and is aimed at eliminating them. In this regard, early pathogenetic therapy for CVD remains an urgent problem in modern science and healthcare. Cell therapy, aimed at eliminating tissue damage underlying the pathogenesis of some pathologies, including CVD, by replacing it with various cells, is of the greatest interest. Currently, cell therapy is the most actively developed and potentially the most effective treatment strategy for CVD associated with atherosclerosis. However, this type of therapy has some limitations. In this review, we have tried to summarize the main targets of cell therapy for CVD and atherosclerosis in particular based on the analysis using the PubMed and Scopus databases up to May 2023.

Keywords: CVD; atherosclerosis; cell therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The main targets for anti-atherosclerotic therapy. AS, atherosclerosis; CVD, cardiovascular disease; ECs, endothelial cells; NO, nitric oxide; oxLDL, oxidized low-density lipoproteins; ROS, reactive oxygen species; SMCs, smooth muscle cells.
Figure 2
Figure 2
Main approaches to CVD cell therapy; BM-MNCs—bone marrow mononuclear cells; ADSCs—adipose-derived stem cells; EPCs—endothelial progenitor cells; iPSCs—pluripotent stem cells; MSCs—mesenchymal stem cells.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tsao C.W., Aday A.W., Almarzooq Z.I., Anderson C.A.M., Arora P., Avery C.L., Baker-Smith C.M., Beaton A.Z., Boehme A.K., Buxton A.E., et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147:e93–e621. doi: 10.1161/CIR.0000000000001123. - DOI - PubMed
    1. Roth G.A., Mensah G.A., Johnson C.O., Addolorato G., Ammirati E., Baddour L.M., Barengo N.C., Beaton A., Benjamin E.J., Benziger C.P., et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update from the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010. - DOI - PMC - PubMed
    1. Libby P., Ridker P.M., Hansson G.K. Progress and Challenges in Translating the Biology of Atherosclerosis. Nature. 2011;473:317–325. doi: 10.1038/nature10146. - DOI - PubMed
    1. Van Camp G. Cardiovascular disease prevention. Acta Clin. Belg. 2014;69:407–411. doi: 10.1179/2295333714Y.0000000069. - DOI - PubMed
    1. Wei J., Xu H., Liese A.D., Merchant A.T., Wang L., Yang C., Lohman M.C., Brown M.J., Wang T., Friedman D.B. Ten-Year Cardiovascular Disease Risk Score and Cognitive Function Among Older Adults: The National Health and Nutrition Examination Survey 2011 to 2014. J. Am. Heart Assoc. 2023;12:e028527. doi: 10.1161/JAHA.122.028527. - DOI - PMC - PubMed

MeSH terms